When high-quality companies trade at 52-week lows, I think it is worth paying attention.
Not because the share price has fallen, but because it forces an important question: has the business deteriorated, or has sentiment simply turned?
Right now, three ASX 200 shares stand out after hitting new lows. But, in my view, each remains a high-quality business despite recent share price weakness.
Image source: Getty Images
Pro Medicus Ltd (ASX: PME)
Pro Medicus has long been one of the ASX's standout growth stories. It has consistently delivered high margins, strong recurring revenue, and a capital-light model that generates impressive returns on equity.
Some investors appear worried that rapid advances in AI could commoditise parts of the medical imaging workflow or reduce the value of premium imaging platforms. When markets get nervous about disruption, high-multiple software names are often the first to be sold.
However, I think it is important to understand what Pro Medicus actually does. Its Visage platform is deeply embedded within hospital systems, handling complex imaging workflows at scale. It is not simply an image viewer. It is a mission-critical, enterprise-grade platform that integrates with hospital IT systems and supports radiologists across large networks.
Management has indicated that it doesn't see AI as a threat to its business model. In fact, it views AI as complementary.
To me, this looks less like structural disruption and more like sentiment-driven volatility. While valuation always matters, I believe the market may be overestimating the AI risk and underestimating the durability of Pro Medicus' competitive position.
Cochlear Ltd (ASX: COH)
Cochlear, another global healthcare leader, has also found itself under pressure.
Short-term challenges, including margin pressure and operational factors, have weighed on sentiment. But the underlying business remains dominant in implantable hearing solutions, with a large installed base and recurring revenue from upgrades and services.
I think it is easy to underestimate how powerful that installed base is. Once a patient is in the Cochlear ecosystem, they are typically there for life. That creates long-term revenue visibility.
When a market leader with decades of innovation trades at a 52-week low, I am inclined to look at the long-term opportunity rather than the most recent headline.
CAR Group Ltd (ASX: CAR)
CAR Group, formerly known as Carsales, operates leading automotive classifieds platforms in Australia and internationally.
The business benefits from network effects. Buyers go where the listings are, and sellers go where the buyers are. That creates a durable competitive advantage.
Share price weakness has reflected softer auto markets and broader tech sentiment. But the long-term shift to digital marketplaces is not reversing. Over time, transaction volumes and pricing power tend to follow platform scale.
If I can buy a market-leading digital classifieds platform at a 52-week low, I see that as an opportunity to accumulate quality.
Foolish Takeaway
A 52-week low does not automatically mean a bargain. Sometimes it signals deeper problems.
But in the case of Pro Medicus, Cochlear, and CAR Group, I believe the core businesses remain strong. Each has global reach, defensible market positions, and structural growth drivers.
